Overview
Harrison.ai develops AI-driven diagnostic tools for healthcare providers that integrate into existing clinical systems (PACS, RIS, EHRs) to help triage, prioritize, and improve accuracy in medical imaging and pathology. Its products include a flagship radiology solution (formerly Annalise.ai) that analyzes imaging studies to identify many findings, Harrison.rad.1, a radiology-focused vision-language model trained on millions of clinical images and reports, and Franklin.ai, a pathology assistant that analyzes tissue to identify diseases and guide treatment. The Harrison.ai Open Platform (HOP) lets healthcare organizations access multiple AI apps from different vendors through a single integration, reducing platform markups. The company aims to address clinician shortages by augmenting radiologists and pathologists, speeding up diagnoses and improving diagnostic accuracy across hospitals and clinics worldwide.
Work here?Claim your company
Simplify's take
What believers are saying
- March 2026 Open Platform added AIRAmed, Koios Medical, Lunit, and Nanox AI.
- September 2026 founders reported A$40 million contracted ARR, quadrupling over eighteen months.
- US revenue exceeded 40 percent, and Frontier Radiology deepened American commercial traction.
What critics are saying
- ABC reported April 2026 redundancies in Australia after the NRFC's A$32 million investment.
- Frontier Radiology creates conflict-of-interest scrutiny because Harrison.ai supplies technology and operations.
- A failed US clinical-services pivot would strand capital and invite regulatory blowback, threatening survival.
What makes Harrison.ai Services unique
- Harrison.ai unifies radiology, pathology, and platform distribution under one clinical workflow stack.
- Its Harrison.rad.1 foundation model targets 455 diagnoses using proprietary clinical images and reports.
- The Open Platform bundles third-party AI with single integration, reducing vendor switching friction.
Help us improve and share your feedback! Did you find this helpful?